Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/100893
Title: | Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study | Authors: | Jarimba, Roberto Saldanha Eliseu, Miguel Nobre Pedroso Lima, João Quaresma, Vasco Moreira, Pedro Nunes, Pedro Coelho Silva, Edgar Tavares da Figueiredo, Arnaldo José |
Keywords: | Prostate cancer; Abiraterone; Enzalutamide; Castration-resistant | Issue Date: | 20-Dec-2021 | Serial title, monograph or event: | Archivio Italiano di Urologia e Andrologia | Volume: | 93 | Issue: | 4 | Abstract: | Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs. | URI: | https://hdl.handle.net/10316/100893 | ISSN: | 2282-4197 1124-3562 |
DOI: | 10.4081/aiua.2021.4.393 | Rights: | openAccess |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.